Skip to main content

Table 1 Histopathological assessment of mice treated with DOTA-Miltuximab® or 6Mbq [177Lu]Lu-DOTA-Miltuximab® on days 3, 5, 7 and 27

From: Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

 6Mbq [177Lu]Lu-DOTA-Miltuximab® DOTA-Miltuximab®
Day3572727
 Mouse numberMouse number
Organ2.23.15.21.12.31.34.45.11.22.12.44.14.24.31.43.23.33.45.35.4
Brain00000000000000000000
Heart00000000000000000000
Lung00000000000000000000
Liver
 Portal neutrophilic infiltrate00000011000000000100
 Focal neutrophilic infiltrate00000000000000000010
 Inflammation, portal00000000000NT03000000
Kidneys
 Tubular epithelial regeneration, cortex00000000000010000100
 Inflammation, interstitial00000000000000000100
Spleen00000000000000NT00000
Small intestine
 Focal neutrophilic infiltrate00010001000001000000
Testes00000000000000000000
  1. NT not tested
  2. 0 = no abnormalities, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe